ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / NEOG / news
CLDX (29) NTLA (25) ORKA (53) LNTH (76) ⌘ Pro Terminal →

Why NEOG Stock Traded Steady Today — RQD Quant Desk Flash

$11.82 0.00% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $11.80

Neogen Corporation (NEOG) carries a Roarable Rating of D (Sell) with 47/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $2.58B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on NEOG Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is NEOG stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Neogen Corporation (NASDAQ: NEOG) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $11.82 (0.00% 1D, market cap $2.58B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 12/20, and Executive Insider Alignment 8/20. Across 1015 tracked Health Care issuers, NEOG ranks #301 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does NEOG compare to CLDX and NTLA in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: In Vitro & In Vivo Diagnostic Substances), NEOG carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of 46.9%, and ROIC of -0.6%. By comparison, CLDX (Celldex Therapeutics Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $2.36B) and NTLA (Intellia Therapeutics Inc.) posts a E grade (25/100 RQD, P/E N/A, ROIC -35.0%, cap $1.75B). Among the 5-stock peer group, LNTH leads on earnings multiple (28.0x) while LNTH leads on capital efficiency (20.3% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for NEOG?
▼

Per NEOG's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-05-31, CIK 0000711377), Neogen Corporation generated $870.4M in revenue (-2.7% YoY), -$7.9M in net income, and $83.2M in free cash flow against $3.36B in total assets and $792.9M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $11.80 (-0.19%)🧬 Disciplined Float (-0.12% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 9.6% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (47/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.9% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510047
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw D- · Rk D+
Cash (7)Whales (10)SEC (10)Macro (12)CEO (8)
Each axis scored 0–20
12M PRICE TARGET CONE-5% Base Target
$15 Bull$11 Base$9 Bear
📬 FREE NEOG RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NEOG)Realized 20D OHLCV Swing Band: ±9.7%
Deterministic 5-Pillar Attribution (47/100 Composite)
🔍 WHY NEOG SCORES 47/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+12/20 pts (26% of score)

FRED Regime × Technicals: 73% of 52W Range • RSI-14 at 45.9 (NEUTRAL RANGE)

▲ #2 Bullish Driver: Whale & Options Positioning+10/20 pts (21% of score)

20D Institutional Volume Accumulation (±9.7% realized swing band)

▼ #1 Drag / Risk Factor: Cash Engine Quality7/20 pts (-13 pt drag)

Capital intensity & 0% operating margin leave 13 pts on the table

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
39
Grade E$11.73-0.1% Next Q
Q2 (-2Q)
42
Grade D$11.72+6.4% Next Q
Q3 (-1Q)
44
Grade D$12.47-5.2% Next Q
Current
47
Grade D$11.82-5.9% Hist 90D α
Trajectory: E (39) → D (47)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a NEOG Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While NEOG currently carries a cautious 47/100 (D) rating due to Cash Engine Quality (7/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($12.24) and Max Pain ($12.41) forces dealer call-delta covering toward $14.97.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.12% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $NEOG• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “NEOG Beats Next Quarter EPS Consensus (Nov 29, 2026) & Holds Above 200D SMA”
YES 47%NO 53%Trade / Inspect Odds →
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →

Why NEOG Stock Traded Steady Today — RQD Quant Desk Flash

Neogen Corporation (NEOG) slipped 0.00% to $11.82, trading at 73% of its 52-week range ($5.37 – $14.26). Stretched risk/reward at current multiples (-1% return on capital) under elevated 10-year interest-rate pressure.

  • ▸Technical Tape: Trading at 73% of its 52-week range ($5.37 – $14.26) with RSI-14 at 45.9 (NEUTRAL RANGE).
  • ▸Volatility Profile: Historical 20-day realized swing band of ±9.7% around $11.82 (no active unusual options sweep snapshot on file).
  • ▸Fundamental Anchor: Roarable D (Sell) backed by 46.9% gross margin and $83.2M annual free cash flow.
Live NEOG Headlines & Catalysts
CATALYSTTradingView • 1d ago
Why Is Neogen Stock Gaining Thursday?

TradingView report covering Neogen Corporation (NEOG) market action, institutional positioning, and fundamental catalysts.

MARKET WIREYahoo • 10d ago
3 Reasons to sell NEOG and 1 stock to buy instead

Neogen’s 25.9% return over the past six months has outpaced the S&P 500 by 16.8%, and its stock price has climbed to $11.78 per share. This was partly thanks to its solid quarterly results, and the run-up might have inve

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NEOG)

  • ✓Walkthrough of NEOG's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
NEOG // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +30.03%▲ ASCENDING CHANNEL
2026-11-03O $12.26H $12.26L $11.82C $11.82VOL 1.95M
RES: $15.40SUP: $10.26SMA50: $12.24SMA200: $10.45
$14.73$12.77$10.81$8.85$6.89RES $15.40SUP $10.26$11.822026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NEOG Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NEOG Butterfly Map → + Track NEOG →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -2.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on NEOG today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NEOG. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for NEOG today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NEOG)

Health Care Rank #301 of 1015 ⚔️ CLDX vs NEOG Full Matrix →

1. Head-to-Head Health Care Peer Comparison (NEOG vs. CLDX, NTLA, ORKA, LNTH)

Industry: Biotechnology: In Vitro & In Vivo Diagnostic Substances (18 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Neogen Corporation (NEOG) ranks #301 by composite RQD confidence (47/100, grade D) and #216 by equity capitalization ($2.58B). Within this direct 5-issuer industry benchmark cohort, LNTH leads on earnings valuation at 28.0x trailing P/E, while LNTH leads on capital efficiency and profitability with 20.3% ROIC and 61.1% gross margin. LNTH currently holds the highest overall quantitative score in the immediate peer group at 76/100 (B+) compared with NEOG at 47/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
NEOG ACTIVE
Neogen Corporation
D 47/100 — 46.9% -0.6% 0.00% $2.58B Benchmark Subject
CLDX
Celldex Therapeutics Inc.
E 29/100 — 87.1% -35.0% -3.52% $2.36B /cldx-vs-neog →
NTLA
Intellia Therapeutics Inc.
E 25/100 — — -35.0% -6.50% $1.75B /ntla-vs-neog →
ORKA
Oruka Therapeutics Inc.
D+ 53/100 — — -18.8% -1.49% $6.41B /orka-vs-neog →
LNTH
Lantheus Holdings Inc.
B+ 76/100 28.0x 61.1% 20.3% -0.15% $6.56B /lnth-vs-neog →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2026-05-31 • CIK 0000711377 ↗

In its most recent audited fiscal period (FY2025, filed 2026-05-31), Neogen Corporation (NEOG) reported GAAP revenue of $870.4M (-2.7% vs. FY2024 revenue of $894.7M , and -5.8% cumulative change since FY2023) , GAAP net income of -$7.9M, operating cash flow of $83.2M, and free cash flow of $83.2M (+43.0% YoY). On the balance sheet, NEOG closed FY2025 with $3.36B in total assets against $792.9M in total debt (Altman Z-Score: 1.45, Piotroski F-Score: 7/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2026-05-31 $870.4M -$7.9M $83.2M $83.2M $3.36B $792.9M
FY2024 (FY) 2025-05-31 $894.7M -$1.09B $58.2M $58.2M $4.05B $889.9M
FY2023 (FY) 2024-05-31 $924.2M -$9.4M $35.3M $35.3M — —

3. NEOG Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NEOG stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Neogen Corporation (NASDAQ: NEOG) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $11.82 (0.00% 1D, market cap $2.58B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 12/20, and Executive Insider Alignment 8/20. Across 1015 tracked Health Care issuers, NEOG ranks #301 in composite RQD confidence.

How does NEOG compare to CLDX and NTLA in the Health Care sector?

Within the Health Care sector (Biotechnology: In Vitro & In Vivo Diagnostic Substances), NEOG carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of 46.9%, and ROIC of -0.6%. By comparison, CLDX (Celldex Therapeutics Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $2.36B) and NTLA (Intellia Therapeutics Inc.) posts a E grade (25/100 RQD, P/E N/A, ROIC -35.0%, cap $1.75B). Among the 5-stock peer group, LNTH leads on earnings multiple (28.0x) while LNTH leads on capital efficiency (20.3% ROIC).

What are the biggest fundamental strengths and SEC risk factors for NEOG?

Per NEOG's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-05-31, CIK 0000711377), Neogen Corporation generated $870.4M in revenue (-2.7% YoY), -$7.9M in net income, and $83.2M in free cash flow against $3.36B in total assets and $792.9M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is NEOG trading relative to its 50-day, 200-day, and 52-week technical levels?

NEOG last traded at $11.82 (0.00% on volume of 2,797,663 shares), positioning the stock -3.43% below its 50-day simple moving average ($12.24) and +13.11% above its 200-day simple moving average ($10.45). Across its 52-week range of $5.37 to $14.26, NEOG sits at the 72.6% percentile with a 14-day RSI of 45.9 (NEUTRAL RANGE) and an implied next-earnings move of ±9.7% ($10.67 to $12.97).

Direct Sub-Reports: NEOG RQD Cockpit NEOG 12M Forecast NEOG Earnings & Move NEOG Dividends & DRIP NEOG Insiders & 13F NEOG Whale Options NEOG Profit Sankey NEOG News & Why
ROARABLE RATING BRIEF • RQD 47/100 (D) ✓ SEC XBRL & RQD VERIFIED

NEOG — Neogen Corporation: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2026-05-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Neogen Corporation (NEOG) earns a live Roarable RQD composite score of 47/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $11.82 (0.00% 1D, market capitalization $2.58B).

  • Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -0.6%, gross margin of 46.9%, operating margin of -2.5%, and free cash flow yield of 3.11%.
  • Whale 13F & Options Flow (10/20) + Insider Conviction (8/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (12/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of 1.45, Piotroski F-Score of 7/9, and Debt/Equity of 0.38x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Neogen Corporation (NEOG) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry. It carries a market capitalization of $2.7B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2026-05-31), Neogen Corporation (NEOG) reported $870.4M in annual revenue (up from $894.7M in FY2024, -2.7% YoY) and -$7.9M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($924.2M revenue, -$9.4M net income) through FY2025, NEOG scaled operating cash flow to $83.2M and free cash flow to $83.2M, backed by $3.36B in total assets against $792.9M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D • RQD 47/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of 3.11% and institutional whale pillar of 10/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 10/20, sustained execution supports upside toward the upper end of the $5.37 – $14.26 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -2.5% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies are therefore — Sector and industry classification (Health Care; In Vitro & In Vivo Diagnostic Substances) is provided, but no sector correlation coefficients or bottleneck mapping are supplied.

  • Key Question #1: Can NEOG sustain or expand its -2.5% operating margin and -0.6% ROIC against Biotechnology: In Vitro & In Vivo Diagnostic Substances peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $870.4M and free cash flow of $83.2M, how will capital allocation balance growth reinvestment against $792.9M in total debt?
  • Key Question #3: How sensitive is NEOG's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

NEOG Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Neogen Corporation (NEOG) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to NEOG Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

NEOG Bull vs. Bear Conversation Board — What's Your Call at $11.82?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON NEOG 🐻 33% BEARISH CONVICTION
1. Pick Your Side on NEOG:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
TA TapeReader_Pro RQD DEBATE OPENER • Price Action & Volume Trader 🐂 BULLISH 🎯 Target: $15.60 (+32.0%)
📌 Pinned Debate

Per the news feed, shares rose 8% on better-than-expected Q1 results and guidance, with Q1 revenue reported at $222.8M against a $208.2

Long NEOG at $11.82 targeting $15.60. Per the news feed, shares rose 8% on better-than-expected Q1 results and guidance, with Q1 revenue reported at $222.8M against a $208.2M estimate.. Institutional whale score is 10/20 and the risk/reward vs. the $5.37 52-week low is skewed heavily in favor of bulls.

SectorRotator 🐂 BULL

@TapeReader_Pro Agree on the RQD 47/100 quality, though with 1.0 beta I'm scaling in with half-size at $11.82 and keeping dry powder in case we test $10.99.

RE RedlineAuditor RQD DEBATE OPENER • Accounting Quality Watch 🐻 BEARISH 🎯 Target: $9.46 (-20.0%)
Spot @ $11.82

Per the RQD rating, ROIC is -0.6% and the Fundamental Cash Engine scores only 7 of 20, with FY 2025 operating income of -$21.6M.

I respect the product at Neogen Corporation, but the stock at $11.82 is a different story. Per the RQD rating, ROIC is -0.6% and the Fundamental Cash Engine scores only 7 of 20, with FY 2025 operating income of -$21.6M.. FCF yield is 3.11% and RQD sits at 47/100 (D) — why pay up here when you can wait for next quarter's numbers?

LIVE TAPE